Editorial: Diagnostic, prognostic and treatment efficacy power of biomarkers of aging for frailty, agerelated diseases and multimorbidity

Stefano Salvioli ^1* Florencia Maria Barbé-Tuana ² Maria Conte ¹

• ¹ Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
• ² Escola Superior de Ciências da Saúde, Brasília, Brazil

papers have been previously demonstrated to be formally associated with age, so it is possible that some of them maintain the association with the observed outcome only in the particular condition that has been reported in the paper.Fourteen original research papers are included in this Research Topic, describing results from studies dealing with different aspects of this biomarkers. In particular, soluble biomarkers, including metabolites have been investigated in diverse clinical or real-world settings. Genetics and epigenetics, as well as functional parameters have been investigated, too.In particular, as far as soluble biomarkers, with a machine learning- As a whole, this collection of papers helps to shed light on the emerging topic of biomarkers of age as useful tools to identify people and patients at risk for specific conditions or, more in general, for frailty and mortality, and to evaluate the efficacy of preventive or therapeutic treatments, not to mention the possibility that these biomarkers are per se possible targets for anti-aging treatments. More extended and (possibly) longitudinal studies will be needed to confirm whether the findings reported in these papers could be translated into clinical practice for diagnostic and prognostic purposes. §S.S. is receiving funds from Next Generation EU, in the context of the National Recovery and Resilience Plan, Investment PE8 -Project Age-It: "Ageing Well in an Ageing Society" CUP: B83C22004800006